
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Bridge Biotherapeutics Becomes BaseLaunch's First Asia Pacific Partner
Details : BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IP...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
